Dose Escalated Concomitant Boost Radiotherapy for Early Breast Cancer

The goal of this prospective, single-arm, phase II, non-randomized trial is to evaluate an hypofractionation schedule with high dose simultaneous integrated tumor bed boost in early breast cancer patients. The main question\[s\] it aims to answer are: * evaluate the rate of all grades of radiation-induced fibrosis at 4 years. * evaluate poor/fair cosmesis rate Participants will be treated with hypofractionated radiotherapy (RT) to whole breast with a dose of 40.05 Gy in 15 fractions (2.67 Gy/die) and a concomitant tumor bed dose of 52.5 Gy (3.5 gy/die)

Trial Details

NCT ID
NCT07021846
Phase
NA
Sponsor
Fondazione Policlinico Universitario Campus Bio-Medico
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • hypofractionated radiotherapy with tumor bed boost
Locations (sample)
  • Roma, Italy|44.99364,11.10642

Key Eligibility Criteria

  • histologically proven breast cancer who have undergone conservative surgery
  • at least 3 inserted clips
  • age: from 18 years old to 50 years
  • at least one of the following risk factors: N1 disease, LVI, extensive intraductal component (\>25%), close margins (\<4 mm), non-hormone-sensitive…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →